Fefer Paul, Beigel Roy, Atar Shaul, Aronson Doron, Pollak Arthur, Zahger Doron, Asher Elad, Iakobishvili Zaza, Shlomo Nir, Alcalai Ronny, Einhorn-Cohen Michal, Segev Amit, Goldenberg Ilan, Matetzky Shlomi
Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Am Heart Assoc. 2017 Jul 25;6(7):e004552. doi: 10.1161/JAHA.116.004552.
Few data are available regarding the optimal management of ST-elevation myocardial infarction patients with clinically defined spontaneous reperfusion (SR). We report on the characteristics and outcomes of patients with SR in the primary percutaneous coronary intervention era, and assess whether immediate reperfusion can be deferred.
Data were drawn from a prospective nationwide survey, ACSIS (Acute Coronary Syndrome Israeli Survey). Definition of SR was predefined as both (1) ≥70% reduction in ST-segment elevation on consecutive ECGs and (2) ≥70% resolution of pain. Of 2361 consecutive ST-elevation-acute coronary syndrome patients in Killip class 1, 405 (17%) were not treated with primary reperfusion therapy because of SR. Intervention in SR patients was performed a median of 26 hours after admission. These patients were compared with the 1956 ST-elevation myocardial infarction patients who underwent primary reperfusion with a median door-to-balloon of 66 minutes (interquartile range 38-106). Baseline characteristics were similar except for slightly higher incidence of renal dysfunction and prior angina pectoris in SR patients. Time from symptom onset to medical contact was significantly greater in SR patients. Patients with SR had significantly less in-hospital heart failure (4% versus 11%) and cardiogenic shock (0% versus 2%) (<0.01 for all). No significant differences were found in in-hospital mortality (1% versus 2%), 30-day major cardiac events (4% versus 4%), and mortality at 30 days (1% versus 2%) and 1 year (4% versus 4%).
Patients with clinically defined SR have a favorable prognosis. Deferring immediate intervention seems to be safe in patients with clinical indices of spontaneous reperfusion.
关于ST段抬高型心肌梗死伴临床定义的自发再灌注(SR)患者的最佳管理,可用数据较少。我们报告了在直接经皮冠状动脉介入治疗时代SR患者的特征和结局,并评估是否可以推迟立即再灌注治疗。
数据来自一项全国性前瞻性调查,即急性冠状动脉综合征以色列调查(ACSIS)。SR的定义预先设定为:(1)连续心电图上ST段抬高降低≥70%,以及(2)疼痛缓解≥70%。在2361例Killip分级为1级的连续ST段抬高型急性冠状动脉综合征患者中,405例(17%)因SR未接受直接再灌注治疗。SR患者在入院后中位数26小时接受干预。将这些患者与1956例接受直接再灌注治疗的ST段抬高型心肌梗死患者进行比较,后者从入院到球囊扩张的中位数时间为66分钟(四分位间距38 - 106分钟)。除SR患者肾功能不全和既往心绞痛发生率略高外,基线特征相似。SR患者从症状发作到就医的时间明显更长。SR患者住院期间心力衰竭(4%对11%)和心源性休克(0%对2%)明显更少(均P<0.01)。住院死亡率(1%对2%)、30天主要心脏事件(4%对4%)、30天死亡率(1%对2%)和1年死亡率(4%对4%)无显著差异。
临床定义的SR患者预后良好。对于有自发再灌注临床指标的患者,推迟立即干预似乎是安全的。